R. Vermeij

发表

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

S. H. van der Burg, C. Melief, C. Melief, 2011, Journal of biomedicine & biotechnology.

Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer

S. H. van der Burg, T. Daemen, R. Vermeij, 2012, International journal of cancer.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

S. H. van der Burg, T. Stijnen, H. Hollema, 2016, Clinical Cancer Research.

Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression

S. H. van der Burg, H. Hollema, A. V. D. Van Der Zee, 2011, Journal of immunotherapy.

Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study

S. H. van der Burg, H. Hollema, J. Bart, 2012, International journal of cancer.

Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen.

T. Daemen, C. Melief, R. Vermeij, 2012, Current pharmaceutical design.

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

H. Hollema, A. V. D. Van Der Zee, G. D. de Bock, 2010, Clinical & developmental immunology.

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists

M. Nishimura, R. Kiessling, A. Karlsson-Parra, 2017, Cancer Immunology, Immunotherapy.

Potentiation of a P53-SLP vaccine by cyclophosphamide in ovarian cancer, A single ARM phase II study

H. Hollema, J. Bart, J. Drijfhout, 2011 .